ABSTRACT
Background Uterine fibroids are common benign tumors during reproductive age. Among pregnant individuals with uterine fibroids, myomectomy at the time of cesarean delivery (CD) allows individuals to avoid a second surgery later in life.
Objective To examine the safety of myomectomy performed at the time of CD and the factors that increase the risk of greater blood loss in cesarean myomectomy.
Study design This was a retrospective cohort study of all cesarean myomectomies (CM) performed at a tertiary care center in Toronto, Ontario between January 1, 2012, and June 1, 2019. The study group included individuals who had CM, and the control group included individuals with fibroids who had a CD without removing their fibroids. The primary outcome was the rate of blood products transfusion. Secondary outcomes were the need for hysterectomy and estimated blood loss (EBL). Subgroup analyses were performed for fibroid size, previous CD, and elective vs urgent CD. Logistic regression analysis was performed to assess for confounders.
Results Overall, 110 CM were compared with 152 CD. The overall transfusion rate for CM was 7.3% compared to 0.7% in the control group (p = 0.005). All procedures requiring transfusion from both groups were performed < 370/7 weeks of gestation. In logistic regression analysis, performing a myomectomy was not associated with a higher risk for transfusion. The only factors associated with transfusion were preterm birth (aOR 14.43, p=0.049) and low pre-operative hemoglobin (aOR 0.90, p=0.02). The median reported EBL was 800 mL for CM and 700 mL for controls (p<0.001). No individuals in either group required concomitant hysterectomy. Subgroup analysis showed that fibroid size ≥5cm and previous CD were not associated with increased risk of transfusion among those who had a CM, while urgent CM was significantly associated with the need for transfusion (p=0.02).
Conclusion This study demonstrates that the transfusion rate was not significantly higher in those undergoing CM at term, compared to those with fibroids undergoing CD without a myomectomy.
Competing Interest Statement
JK was on the speakers bureaus and receives consulting fees from Abbvie corporation and Pfizer, consulting fees from Ethicon and Organon
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Board of Sunnybrook Health Sciences Centre gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
